Compare AISP & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AISP | CRBU |
|---|---|---|
| Founded | 2006 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 112.1M | 203.9M |
| IPO Year | N/A | 2021 |
| Metric | AISP | CRBU |
|---|---|---|
| Price | $3.08 | $1.82 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $9.33 |
| AVG Volume (30 Days) | 806.0K | ★ 999.3K |
| Earning Date | 11-17-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $12,033,886.00 | $9,295,000.00 |
| Revenue This Year | $34.52 | N/A |
| Revenue Next Year | $59.54 | $4.96 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.85 | $0.66 |
| 52 Week High | $7.66 | $3.54 |
| Indicator | AISP | CRBU |
|---|---|---|
| Relative Strength Index (RSI) | 33.91 | 40.56 |
| Support Level | $3.47 | $1.82 |
| Resistance Level | $3.92 | $1.91 |
| Average True Range (ATR) | 0.23 | 0.10 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 8.50 | 28.90 |
Airship AI Holdings Inc is a robust AI-driven data management platform that solves complex data challenges for large institutions operating in dynamic and mission-critical environments with rapidly increasing volumes of data being ingested from a similarly rapidly growing number of data sources. Its primary offerings include Outpost AI, Acropolis, and Airship Command. Its offerings allow customers to manage their data across the full data lifecycle, when and where need it, using a secure permission-based architecture.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.